Fusion protein comprising interleukin-2 and interleukin-33

Patent metadata

Field	Value
Publication number	US-9840545-B2
Application number	US-201415026927-A
Country	US
Kind code	B2
Filing date	Sep 22, 2014
Priority date	Sep 20, 2013
Publication date	Dec 12, 2017
Grant date	Dec 12, 2017

Abstract

The present application discloses a novel fusion peptide of IL-2 and IL-33 and its use. It comprises a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment or homolog thereof, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment or homolog thereof. The two portions can be linked by a linker sequence. The application discloses that combination therapies using IL-2 and IL-33 or a therapy using the IL233 fusion protein are effective in preventing or treating diseases and disorders such as autoimmune diseases and disorders, inflammation, etc. Depending on the subject's disease or disorder, the compositions of the invention are useful for preventing certain symptoms, treating the disease, and alleviating at least some of the symptoms.

First claim

What is claimed is:

1. A fusion protein comprising a biologically active domain of Interleukin-2 (IL-2) or a biologically active fragment thereof, wherein said domain binds with the IL-2 receptor, and a biologically active domain of Interleukin-33 (IL-33) or a biologically active fragment thereof, wherein said IL-33 domain binds with the IL-33 receptor, further wherein said IL-2 domain is linked to said IL-33 domain with a linker sequence.

2. The fusion protein of claim 1 , wherein said protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO: 11.

3. The fusion protein of claim 1 , wherein said linker comprises the sequence of SEQ ID NO:5.

4. The fusion protein of claim 1 , wherein said IL-2 comprises the sequence of SEQ ID NO:6 or SEQ ID NO:8 and said IL-33 comprises the sequence of SEQ ID NO:7 or SEQ ID NO:9, or biologically active fragments thereof.

5. The fusion protein of claim 4 , wherein said fragment of IL-2 comprises the sequence of SEQ ID NO:3, and said fragment of IL-33 comprises the sequence of SEQ ID NO:4, or biologically active fragments thereof.

6. The fusion protein of claim 5 , wherein said IL-2 comprises of at least 95% identity with SEQ ID NO:3 and said IL-33 comprises at least 95% identity with SEQ ID NO:4.

7. The fusion protein of claim 1 , wherein said protein is a synthetic protein.

8. A pharmaceutical composition comprising the fusion peptide of claim 1 , a pharmaceutically-acceptable carrier, and optionally an additional therapeutic agent.

Assignees

• Univ Virginia Patent Foundation

Inventors

• Sharma Rahul
• Okusa Mark D

Classifications

• C07K14/54

  Interleukins [IL] · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• C07K14/55 Primary

  IL-2 · CPC title

• C07K2319/74

  containing a fusion for binding to a cell surface receptor · CPC title